364 related articles for article (PubMed ID: 34683830)
21. Active targeting strategies for anticancer drug nanocarriers.
Basile L; Pignatello R; Passirani C
Curr Drug Deliv; 2012 May; 9(3):255-68. PubMed ID: 22452402
[TBL] [Abstract][Full Text] [Related]
22. The ligand nanoparticle conjugation approach for targeted cancer therapy.
Karra N; Benita S
Curr Drug Metab; 2012 Jan; 13(1):22-41. PubMed ID: 21892918
[TBL] [Abstract][Full Text] [Related]
23. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting.
Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Patel RJ; Ajazuddin ; Ravichandiran V; Murty US; Alexander A
J Control Release; 2020 May; 321():372-415. PubMed ID: 32061621
[TBL] [Abstract][Full Text] [Related]
24. Exploring Therapeutic Potential of Nanocarrier Systems Against Breast Cancer.
Kumar L; Baldi A; Verma S; Utreja P
Pharm Nanotechnol; 2018; 6(2):94-110. PubMed ID: 29866028
[TBL] [Abstract][Full Text] [Related]
25. Colloidal Nanocarriers as Versatile Targeted Delivery Systems for Cervical Cancer.
Sugumaran A; Mathialagan V
Curr Pharm Des; 2020; 26(40):5174-5187. PubMed ID: 32586249
[TBL] [Abstract][Full Text] [Related]
26. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
Tyagi P; Subramony JA
J Control Release; 2018 Feb; 272():159-168. PubMed ID: 29355619
[TBL] [Abstract][Full Text] [Related]
27. PEGylated nanocarriers: A promising tool for targeted delivery to the brain.
Gajbhiye KR; Pawar A; Mahadik KR; Gajbhiye V
Colloids Surf B Biointerfaces; 2020 Mar; 187():110770. PubMed ID: 31926790
[TBL] [Abstract][Full Text] [Related]
28. Transition from passive to active targeting of oral insulin nanomedicines: enhancement in bioavailability and glycemic control in diabetes.
Kaklotar D; Agrawal P; Abdulla A; Singh RP; Mehata AK; Singh S; Mishra B; Pandey BL; Trigunayat A; Muthu MS
Nanomedicine (Lond); 2016 Jun; 11(11):1465-86. PubMed ID: 27171572
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
30. Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking.
Conniot J; Silva JM; Fernandes JG; Silva LC; Gaspar R; Brocchini S; Florindo HF; Barata TS
Front Chem; 2014; 2():105. PubMed ID: 25505783
[TBL] [Abstract][Full Text] [Related]
31. Nanocarriers for diagnosis and targeting of breast cancer.
Sharma A; Jain N; Sareen R
Biomed Res Int; 2013; 2013():960821. PubMed ID: 23865076
[TBL] [Abstract][Full Text] [Related]
32. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes.
Gaber M; Medhat W; Hany M; Saher N; Fang JY; Elzoghby A
J Control Release; 2017 May; 254():75-91. PubMed ID: 28365294
[TBL] [Abstract][Full Text] [Related]
33. Polymeric Lipid Hybrid Nanoparticles: Properties and Therapeutic Applications.
Jose C; Amra K; Bhavsar C; Momin M; Omri A
Crit Rev Ther Drug Carrier Syst; 2018; 35(6):555-588. PubMed ID: 30317969
[TBL] [Abstract][Full Text] [Related]
34. Lipid-based Nanocarriers for Cancer and Tumor Treatment.
Ansari MT; Ramlan TA; Jamaluddin NN; Zamri N; Salfi R; Khan A; Sami F; Majeed S; Hasnain MS
Curr Pharm Des; 2020; 26(34):4272-4276. PubMed ID: 32693760
[TBL] [Abstract][Full Text] [Related]
35. Recent progress of drug nanoformulations targeting to brain.
Khan AR; Yang X; Fu M; Zhai G
J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256
[TBL] [Abstract][Full Text] [Related]
36. Recent Advances in Nanotechnology-Based Targeted Therapeutics for Breast Cancer Management.
Alhalmi A; Beg S; Almalki WH; Alghamdi S; Kohli K
Curr Drug Metab; 2022; 23(8):587-602. PubMed ID: 35657282
[TBL] [Abstract][Full Text] [Related]
37. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
[TBL] [Abstract][Full Text] [Related]
38. Lipid-based nanoparticles and RNA as innovative neuro-therapeutics.
Tsakiri M; Zivko C; Demetzos C; Mahairaki V
Front Pharmacol; 2022; 13():900610. PubMed ID: 36016560
[TBL] [Abstract][Full Text] [Related]
39. Bioanalytical strategies to evaluate cisplatin nanodelivery systems: From synthesis to incorporation in individual cells and biological response.
Gutierrez-Romero L; Díez P; Montes-Bayón M
J Pharm Biomed Anal; 2024 Jan; 237():115760. PubMed ID: 37839264
[TBL] [Abstract][Full Text] [Related]
40. A Review on the Delivery of Plant-Based Antidiabetic Agents Using Nanocarriers: Current Status and Their Role in Combatting Hyperglycaemia.
Zolkepli H; Widodo RT; Mahmood S; Salim N; Awang K; Ahmad N; Othman R
Polymers (Basel); 2022 Jul; 14(15):. PubMed ID: 35893954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
